Clinical Trial Update: Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy and safety of Zomig Nasal Spray for acute migraine in children aged 6 to 11 years with ongoing open-label extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Zomig nasal spray (zolmitriptan)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Migraine | Phase 3 | Status: COMPLETED